A Phase 1 Repeated Dose Open Label Study to Investigate the Pharmacokinetics and Safety of Naproxcinod 750mg Bid Administered to Patients With Impaired Renal Function Compared to Matching Healthy Subjects.
Latest Information Update: 04 Feb 2009
At a glance
- Drugs Naproxcinod (Primary)
- Indications Osteoarthritis
- Focus Pharmacokinetics
- Sponsors NicOx
- 04 Feb 2009 New trial record